(Q38125031)

29 August 2017

title

Molecular neuro-oncology in clinical practice: a new horizon (English)

1 reference

29 August 2017

1

Michael Weller

1 reference

29 August 2017

3

Wolfgang Wick

1 reference

29 August 2017

5

Guido Reifenberger

1 reference

29 August 2017

2

Stefan M Pfister

1 reference

29 August 2017

4

Monika E Hegi

1 reference

29 August 2017

6

Roger Stupp

1 reference

29 August 2017

publication date

1 August 2013

1 reference

Lancet Oncology Commission

29 August 2017

published in

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

e370-9

1 reference

The 2007 WHO classification of tumours of the central nervous system

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Molecular markers in low-grade gliomas: predictive or prognostic?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Altered telomeres in tumors with ATRX and DAXX mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Epidermal growth factor receptor: a re-emerging target in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

MAPK pathway activation in pilocytic astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Targeted therapy for BRAFV600E malignant astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EOR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Gene expression profiling and genetic markers in glioblastoma survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

A tumorigenic MLL-homeobox network in human glioblastoma stem cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

A multigene predictor of outcome in glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

An integrated genomic analysis of human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Molecular staging of intracranial ependymoma in children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Molecular approaches to ependymoma: the next step(s).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Cross-species genomics matches driver mutations and cell compartments to model ependymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Radial glia cells are candidate stem cells of ependymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

A prognostic gene expression signature in infratentorial ependymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Adult medulloblastoma comprises three major molecular variants.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

The clinical implications of medulloblastoma subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Molecular subgroups of medulloblastoma: the current consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Advances in meningioma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970168-2

7 January 2021

10.1016/S1470-2045(13)70168-2

Identifiers

DOI

1 reference

29 August 2017

1 reference